Patients with the lupus anticoagulant are known to have an increased tendency to develop thromboembolic complications. This has been reported only rarely, however, in young children. We report a case of extensive thrombosis in a 5 year old girl with systemic lupus erythematosus and autoimmune haemolytic anaemia.
Case report A 5 year old Chinese girl first presented with a history of fever and progressive pallor for one month. Clinical examination revealed striking pallor, bilateral cervical lymphadenopathy, and hepatosplenomegaly.
Laboratory investigations showed a haemoglobin concentration of 3-7 g/dl, white blood cell count Treatment was tailed down gradually and she is now on alternate day prednisolone (5 mg every other day). The lupus anticoagulant factor remained positive in her serum a month after discharge. Her condition has remained stable apart from blindness of the left eye and the self amputated stump of the right hand.
Discussion
Our patient was diagnosed as having systemic lupus erythematosus at a very young age of 4 years, with autoimmune haemolytic anaemia as the presenting manifestation. A year later she developed extensive thromboses, involving the retinal veins, superficial veins of hands and feet, and most probably the cerebral veins as well, manifesting as cerebral infarction. Although thrombosis is a well recognised complication of systemic lupus erythematosus and is known to occur in renal, retinal, cerebral, pulmonary, and leg veins, it is rare for it to affect multiple sites simultaneously as it did in our patient. The coagulation screen confirmed the presence of circulating lupus anticoagulant.
The lupus anticoagulant is an acquired inhibitor of the prothrombin complex (factor XA, factor V, calcium, and phospholipid). Patients with circulating lupus anticoagulant, paradoxically, have increased thrombotic activity, and bleeding tendency seems to be uncommon, except in cases with coexisting thrombocytopenia.
Steroids, non-steroidal anti-inflammatory drugs, and cytotoxic agents have been used by others without any effect on the presence of the lupus anticoagulant.5 Other modalities of treatment are anticoagulant treatment and plasma exchange. There have been insufficient data to conclude about the efficacy of such forms of treatment. Use of prostacyclin rather than anticoagulants in acute management is worthy of consideration. Intravenous prostacyclin has been used in severe Raynaud's phenomenon. To date there has been no report of its use in systemic lupus erythematosus with the lupus anticoagulant. Our patient responded well to treatment with steroids and has remained in a satisfactory condition on low dose steroids. She has, however, a possible long term risk of having repeated spontaneous abortions and intrauterine deaths when she reaches reproductive age.6 SUMMARY Swivel walkers were used to provide low energy ambulation in 11 boys with Duchenne muscular dystrophy in schools for the physically handicapped in South Glamorgan. Our preliminary experience suggests that these walkers improve the quality of life and provide a useful part of the physical treatment of the condition.
There are clear advantages in prolonging the mobilisation of boys with Duchenne muscular dystrophy, most particuarly in improving morale. The use of long leg calipers was first advocated by Spencer and Vignos in the United States' and has been used in the United Kingdom, particularly at the Hammersmith Hospital.2 Nevertheless, this approach has not been universally accepted. There have been difficulties with stability, with the boys falling over easily, fitting can be complicated, and the period that the walking is prolonged can be a short one.
Swivel walkers were first introduced in America for children with amelia. The principle of their use is a pylon arrangement that uses side to side oscillation together with a forward centre of gravity to provide ambulation. Their use for children with a paraplegia was pioneered in the United Kingdom by Rose.3 Their use for patients with muscular dystrophy was first suggested in the United Kingdom in 1981, providing a means of low energy ambulation for the boys, and has been developed by Bennett.4 We describe our preliminary experience with swivel walkers in boys with Duchenne muscular dystrophy in schools for the physically handicapped in South Glamorgan.
Methods and results
Most of the boys with Duchenne muscular dystrophy at the special schools for the physically handicapped in South Glamorgan (Pentwyn and Erw'r Delyn) have actively chosen to use swivel walkers as part of a programme of physical treatment for their condition. This programme has been part of a multidisciplinary, problem orientated approach to muscle disease centred at the muscle clinic and regional genetic centre at the University Hospital of Wales (Professor P Harper and Dr J R Sibert). As well as dealing with the physical problems we offer a comprehensive genetic service and active help in resolving any problems in the home situation.
In 1984 swivel walkers were introduced into the special schools and up to now have been used by 11 boys. Only one boy had declined to participate because he felt unwilling to have the extra physiotherapy involved. We have used two types of swivel walkers: initially, we used the Shrewsbury type, but more recently we have had good experience with the Salford swivel walker. We have reason to believe that the Orlav swivel walker would also be satisfactory. Elective operations on the Achilles tendons have been performed in most boys to help wheelchair position and comfort and to help with the use of the swivel walkers.
The boys are placed in their swivel walkers by physiotherapists and helpers and are encouraged to walk. It takes two people about three minutes to place a boy in a walker. The boys can use their swivel walkers to go between classes or can be taken
